Switch study for people with insomnia using dolutegravir
St Mary’s London and Royal Sussex Brighton
A new study being run in London and Brighton is looking to recruit 46 adults who are experiencing sleep problems using dolutegravir-based ART. 
The study will look at whether switching ART from Triumeq (abacavir/lamivudine/dolutegravir) to Biktarvy (tenofovir-AF/emtricitabine/bictegravir) is associated with improved sleep.
Half the participants will switch and half will continue on their current treatment.
The study will look at brain function using two functional MRI brain imaging scans. It will also include participant questionnaires, including on sleep quality.
The study involves six routine clinic visits over five months and two scanning visits.
It is running at St. Mary’s Hospital in London and Brighton and Royal Sussex County Hospital in Brighton. It is funded by Gilead Sciences. HIV positive people are able to self-refer if interested.
Please email the study team if you would like more information or if you are interested in joining.
Further details are also online. 
Bictegravir central nervous system (CNS) study. ICRCTN register 17508886.
This report was first published on 8 October 2021.